myNEO
Ottergemsesteenweg-Zuid 808 B511
9000 Gent
BE
myNEO
Foundation date
01/12/2018
Sector
#Biotechnology / R&D ServicesSubsector
- #Therapeutics - Cell therapy
- #Therapeutics - Peptides
- #R&D Services - Bioinformatics
- #R&D Services - CRO (Contract Research Organization)
- #R&D Services - Genomics
Therapeutic areas
myNEO is a distinguished Belgian biotech powerhouse dedicated to pioneering breakthrough immunotherapies tailored to target diverse tumor profiles. myNEO's discovery platform leverages immuno-genomic datasets to identify tumor alterations and unveil promising and largely untapped immunotherapeutic targets. In vivo studies underscore myNEO's prowess in identifying effective tumor targets. myNEO is now advancing development of its proprietary 'camyotopes', a class of long non-coding RNAs that shows selective translation in tumor tissue and a robust immunogenic multi-targeted response against the tumor. The lead program CAMYO-01 will validate the MOA of the camyotopes in a CRC phase I/II trial, while simultaneously expanding the development pipeline to other indications.
Upcoming events
All events-
1804 '24
Anglonordic Life Science Conference 2024
Event by: BioPartner -
1605 '24
Knowledge for Growth 2024
Event by: flanders.bio -
2304 '24
BioTrinity 2024
Event by: OBN
Latest news
More news-
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Wednesday March 27th 2024
Read more
-
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline
Tuesday March 26th 2024
Read more
-
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
Monday March 25th 2024
Read more
Jobs
More jobs-
28/03/24
Flemish Brabant
Post-doc position – Structural Bioinformatics of protein interactions
Permanent
VIB -
-
More info?
Ellen Telleir
Communication Coordinator